Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3, 1996, Pages 247-252

  Kim, Young Hoon ^a   Cha, In June ^a   Shim, Joo Chul ^a   Shin, Jae Gook ^a   Yoon, Young Ran ^a   Kim, Yong Kwan ^a   Kim, Jung Ik ^a   Park, Geun Hong ^b   Jang, In Jin ^c   Woo, Jong Inn ^c   Shin, Sang Goo ^c  

^a Inje University College of Medicine   (South Korea)

^b Dongsuh Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; RIFAMPIN; SCHIZOPHRENIA; TUBERCULOSIS;

EID: 8944229700     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606000-00010     Document Type: Article

References (30)

1. World Health Organization. World tuberculosis toll on the rise. Asian Med News 1991;3:9.
2. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger, 1985.
3. Twum-Barima Y, Carruthers SG. Quinidine-rifampin interaction. N Engl J Med 1981;304:1466-9.
4. Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG. Time course of the changes in prednisolone pharmacokinetics after coadministration or discontinuation of rifampin. Eur J Clin Pharmacol 1993;45:287-3.
5. Kay L, Kampmann JP, Svendsen TL. Influence of rifampin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985;20:323-6.
6. Hansten PD. Drug interactions that inhibit oral contraceptive efficacy. Drug Interact Newsl 1981;1:9-11.
7. Baciewicz AM, Self TH, Bekenmeyer WB. Update on rifampin drug interactions. Arch Intern Med 1987;147:565-8.
8. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992;152:711-6.
9. Takeda M, Nishimura K, Yamashita S, Matabayashi T, Taninos S, Nishimura T. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. Clin Neuropharmacol 1986;9:386-97.
10. Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL, Korchinsky ED, McKay G. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 1989;9:98-104.
11. Froemming JS, Francis Lam YW, Jan MW, Davis CM. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989;17:396-423.
12. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
13. Lewin RJ, Fogg L, Meltzer HY. Assessment of negative and positive symptoms in schizophrenia Schizophr Bull 1983;9:368-76.
14. Miller R, DeVane CL. Measurement of haloperidol and reduced haloperidol in human plasma using reversed phase high performance liquid chromatography. J Chromatogr A 1986;374:405-8.
15. Ferry PJ, Pfohl BM, Kelly MW. The relationship of haloperidol concentrations to therapeutic response. J Clin Psychopharmacol 1988;8:38-43.
16. Pieters FAJM, Woonink F, Zuidema J. Influence of once-monthly rifampin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria. Eur J Clin Pharmacol 1988;34:73-6.
17. Ahmad D, Mathur P, Ahuja S. Rifampin-quinidine interactions. Br J Dis Chest 1979;73:409-11.
18. Syvalahti EK, Phlajamaki KK, Iisalo EJ. Rifampin on drug metabolism. Lancet 1974;2:232-3.
19. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1984;311:1681-3.
20. Bennett PN, John VA, Whitmarsh VB. Effect of rifampin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol 1982;13:387-91.
21. Pratt WB, Taylor P. Principles of drug action: the basis of pharmacology. 3rd ed. New York: Churchill Livingstone, Inc., 1990:436-8.
22. Knoben JE, Anderson PO. Handbook of clinical drug data. 6th ed. Hamilton, IL: Drug Intelligence Publications, Inc., 1988:372-4.
23. Jazequel AM, Orlandi F, Teuconi LT. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea pig hepatocytes. Gut 1971;12:984-7.
24. Bolt HM, Koppus H, Bolt M. Effect of rifampin treatment on the metabolism of oestradiol and 17-ethinylestradiol by human liver microsomes. Eur J Clin Pharmacol 1975;8:301-7.
25. Bachmann K, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993;23:307-15.
26. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
27. Shaw GL, Falk RT, Deslauriers J, Nesbitt JC, McKneally MF, Frame JN, Feld R, Issaq HJ, Ruckdeschel JC, Hoover RN. Lung tumor resection does not affect debrisoquine metabolism. Cancer Epidemiol Biomarkers Prev 1994;3:141-4.
28. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos Biol Fate Chem 1985;13:443-8.
29. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (spartein/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31:655-60.
30. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.